NICE is considering whether the definition of rapidly evolving severe multiple sclerosis in the recommendation wording of TA616 Cladribine for treating relapsing-remitting multiple sclerosis should be updated.
Following the consultation, NICE will determine whether an update to the recommendation is needed and update stakeholders.
This page was last updated: